Abstracts

CELL-FREE DNA PREDICTS HIV REBOUND TIMING FOLLOWING ANTIRETROVIRAL THERAPY CESSATION

The development of HIV cure strategies depends on our capacity to predict HIV rebound when antiretroviral therapy (ART) is stopped. Here, we applied a systems profiling approach to the analytical treatment interruption (ATI) framework, to identify circulating plasma factors that enable non-invasive prediction of viral rebound kinetics post-ART cessation. Plasma samples were retrospectively collected from…

IMMUNE MARKERS AND TO TIME TO REBOUND DURING HIV TREATMENT INTERRUPTION IN ACTG A5345

Understanding factors that affect viral rebound timing during antiretroviral treatment interruption will accelerate efforts toward inducing sustained HIV remission. We evaluated whether immunologic parameters prior to treatment interruption are predictive of time to rebound in individuals interrupting ART in a highly monitored setting. A5345 enrolled individuals who started ART in chronic or early infection and…

ACTIVATING PKC-? INDUCES HIV EXPRESSION WITH IMPROVED TOLERABILITY

Activation of latent HIV could increase elimination of infected cells by therapeutics that directly target infected cells or stimulate antiviral immunity, potentially leading to long-term remission or cure. Protein kinase C (PKC) agonists are highly effective at activating latent HIV in vitro. We previously found that platelet activation is associated with toxicity of novel PKC…

VENETOCLAX SIGNIFICANTLY REDUCES HIV VIRAL LOAD IN VIVO AND IN VITRO

The BCL-2 pro-survival protein has been implicated in HIV persistence, and we have previously demonstrated that the clinically used BCL-2 inhibitor Venetoclax augments HIV induced killing of the reactivating cell, in vitro. It is unknown whether Venetoclax impacts HIV dynamics in vivo. We hypothesized that Venetoclax would reduce HIV replication in a murine model of…

AUTOLOGOUS VIRUS-NEUTRALIZING ANTIBODIES DELAY VIRUS REBOUND IN INFANT SHIV MODEL

Early ART improves disease outcomes in infected children but does not eliminate latent HIV reservoirs. Studies in a small subset of perinatally infected children who developed HIV-specific antibody responses and remained virus free when ART was interrupted, suggested that autologous antibody responses maybe important for sustained viral control and lack of virus rebound. However, kinetics…

VIRUS REMISSION WITH AN OPTIMIZED EARLY ART REGIMEN IN MACAQUES

Early initiation of antiretroviral therapy (ART) does not cure HIV in humans or SIV in macaques due to rapid viral reservoir establishment. Here, we investigated in macaques if a novel ART regimen, designed to have robust penetration in virus reservoir sites, can result in virus remission after treatment cessation. The ART regimen included daily tenofovir…